Phospholipase D (PLD) hydrolyses phosphatidylcholine into phosphatidic acid (PA) and choline. Our work aims to understand the properties of PLD1, and to identify downstream targets of PA. In one set of projects, we have focused on membrane-targeting mechanisms and have proposed a hierarchy of signals that allows PLD1 to localize to intracellular membranes. These signals involve a functional pleckstrin homology (PH) domain and its fatty acylation on two adjacent cysteine residues. A nearby Phox homology (PX) domain may modulate the function of the fatty acylated PH domain. This complex array of signals is probably necessitated by the targeting of PLD1 to multiple endocytic and secretory membranes under basal and signal-dependent conditions. In another set of projects, we have used chemically synthesized PA coupled to a solid support in order to identify proteins that interact with this phospholipid. Several proteins have emerged from this screen as potential targets. Some (e.g. ADP-ribosylation factor, coatomer β subunit) are involved in trafficking and their PA affinity can be understood in terms of their regulated cycling on and off membranes during rounds of transport. Others (sphingosine 1-phosphate kinase and PtdIns4P 5-kinase) are implicated in pathways that also involve PLD activation. Others still are novel proteins (brain-specific neurochondrin) whose affinity for PA may contribute to an understanding of their cellular function.
Introduction
Enzymes of the phospholipase D (PLD) family have been studied for over 40 years now, yet the signalling pathways in which they are implicated are still a matter of debate and an intense focus of investigation. PLD enzymes hydrolyse phosphatidylcholine (PC) to generate membrane-bound phosphatidic acid (PA) and soluble choline [1] . Whereas choline formation may be important for some aspects of PLD function, it is thought that formation of PA (and its downstream metabolite diacylglycerol) constitutes the crucial contribution of the enzyme to PLD-dependent signalling pathways. PA is an abundant cellular phospholipid that is synthesized by several distinct routes [2] . In terms of altering the overall PA mass in cells, the PLD contribution is negligible. Therefore PLD activity can influence only the localized levels of PA, suggesting that, in order to understand how PLD contributes to cellular signalling, it is important to understand in detail the cellular sites of PLD expression and its mode of regulation.
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aspects: it is found primarily on intracellular membranes and it is active in vivo but inactive in vitro, unless stimulated with a variety of activators. Extensive biochemical work has identified several PLD activators, including protein kinase C (PKC), ADP-ribosylation factor (Arf) family members, Rho family members and the lipid PtdIns(4,5)P 2 (PIP 2 ) [1, 4] .
The subcellular localization of PLD1 has been investigated using both epitope-tagged overexpressed protein and antibodies to the endogenous counterpart [5] . The results that have been reported are variable, and seem to depend significantly on the cell type under investigation. Agreement exists that, in adherent cells, PLD1 localizes primarily on punctate structures near or at the Golgi complex. These punctate structures have been reported to correspond to endosomal or secretory vesicles, or tubulovesicular clusters [6] . In contrast, PLD1 seems to localize to cytoskeletal elements of non-or semi-adherent cells, especially those of immune origin [7] .
Membrane targeting of PLD1
The primary sequence of PLD1 reveals no transmembrane domains or canonical lipid modification sites and therefore cannot explain the consistent finding that the protein is almost always found associated with membrane fractions in tissues and adherent cells [8] . Instead, the primary sequence reveals two membrane-targeting determinants at the Nterminus of PLD1 [a pleckstrin homology (PH) domain, and a Phox homology (PX) domain] that could explain regulated translocation of the protein from the cytosol to membranes. Despite the absence of a canonical sequence, we explored the possibility that PLD1 becomes modified with lipids by labelling cells overexpressing PLD1 with tritiated palmitate and recovering labelled protein by immunoprecipitation. We found that PLD1 labels strongly with palmitate and, in subsequent experiments, identified cysteine residues 220 and 221 as the sites of palmitoylation [9, 10] . Interestingly, these residues fall within the PLD1 PH domain (Figure 1 ), and it then became necessary to understand how the three potential membrane-targeting determinants of PLD1 (a PX domain, a PH domain and a palmitoylation site) contribute to membrane binding. To address this question, we mutated the PLD1 PH domain in three different PLD1 constructs: the full-length wild-type protein, the mutant that is missing the palmitoylation sites, and a truncation mutant that is missing the entire PX domain [11] . We found that the mutant missing the PX domain was palmitoylated normally and it localized to the same sites as the full-length protein.
Therefore, under basal conditions, the PX domain is dispensable for membrane targeting. Mutants with amino acid changes that impair the PH domain were severely defective for both membrane binding and palmitoylation. The latter is surprising since the palmitoylation sites are intact in these PH domain point mutants. The simplest explanation for this result is that a functional PH domain is important for both initial membrane targeting and palmitoylation. Therefore palmitoylation must serve two functions: to make membrane interaction stronger and to specify correct localization. Experimental evidence supporting both of these functions has been provided by both ourselves and others. First, mutants with impaired palmitoylation sites are not localized to punctate structures that are characteristic of wild-type PLD1 distribution [10] . Secondly, the affinity of non-palmitoylated PLD1 for membranes (i.e. its extractability from membranes with salts or detergents) is much lower than that of the fully palmitoylated protein [12] .
This hierarchy of membrane-targeting signals explains some, but not all, of the observations that concern PLD1 localization. For example, mutation of the PIP 2 -binding region (see Figure 1) , or truncation of the C-terminus have both been reported to redistribute the protein to the cytosol [13, 14] . In addition, a point mutation in PLD1 (Ser 911 →Ala) that impairs catalysis also causes cytosolic redistribution [9] . We do not understand the basis for these observations. It is possible that a truly unusual and extensive array of membrane-targeting determinants is ultimately at work for PLD1. Alternatively, it is more attractive to speculate that the PLD1 PH domain and its fatty acylation are extremely sensitive to the overall structure of the protein. In this view, mutations that are spatially distant from the PH domain can somehow render this domain non-functional and prohibit membrane binding. Some support for this idea comes when considering the Ser 911 →Ala mutant. Exton and coworkers have shown that functional PLD1 can be obtained by expressing the N-and C-terminal halves of the protein separately. This interdomain interaction is also required for palmitoylation, and it is inhibited in the Ser 911 →Ala mutant [12] . Therefore the Ser 911 →Ala mutant is a good example of a protein that loses membrane binding because of structural reasons that ultimately impinge on the functionality of the PH domain and its fatty acylation.
Potential PA targets
The search for direct downstream targets of PLD activity has been less successful than the usually concurrent identification of cellular pathways in which PLD is implicated. The latter has been productive because it is very easy to measure the PLD product unambiguously. Primary alcohols divert formation of PA into the more stable and PLD-specific phosphatidyl alcohol. Identification of this signature PLD product by TLC has resulted in long lists of cells or tissues that exhibit elevated PLD activity following stimulation with agonists and other compounds [4] . In contrast, direct downstream targets of PLD, i.e. PA-binding proteins, have been more elusive because PA is unstable, and it is not always clear whether it or diacylglycerol constitutes the relevant candidate. Nevertheless, in the last few years some PA-binding candidates have been proposed, including the Src homology 2 (SH2)-domain-containing protein-tyrosine phosphatase, SHP-1 [15] , the serine/threonine kinase, Raf-1 [16] , the cAMP-specific phosphodiesterase, PDE4D3 [17] , the mammalian target of rapamycin (mTOR) [18] (A)
and the protein phosphatase-1 (PP1) [19] . In the cases of Raf-1 and PDE4D3, further analysis of PA binding has led to the identification of short amino acid regions that account for interaction with the phospholipid [16, 20] . So far, a 'universal' PA-binding module that is common to many different proteins and has similar properties to other lipidbinding modules (e.g. PH domains, PX domains or FYVE domains) has not been discovered, perhaps suggesting that the structural requirements for such a module are very simple and heterogeneous.
To identify potential PA-binding proteins on a large scale, we have synthesized a modified form of PA that can easily be coupled to a solid support, Affigel-10 [21] (Figure 2) . We have assumed that these pure PA-coupled beads would allow purification of at least one class of PA-binding proteins: those that interact strongly with PA without the need of additional components (e.g. of other phospholipids). We are working on three classes of such proteins.
Traffic-related PA-binding proteins Total brain cytosol was mixed with PA-coupled beads and the bound proteins were resolved by PAGE and identified by MS. Four proteins thus identified were already known to be involved in intracellular traffic: Arf, the β subunit of coatomer, kinesin and N-ethylmaleimide-sensitive factor (NSF) [22] . None of the four proteins bound strongly to any other lipid-coupled beads such as PIP 2 and their binding to immobilized PA was inhibited by soluble lipid. For all four proteins, we characterized further PA binding. For example, we found that myristoylation of Arf was absolutely required for PA binding and, in addition, Arf mutants with enhanced GTP affinity bound to PA much stronger than the wildtype counterpart. In contrast, the inactive ADP-bound form of NSF showed the strongest binding to PA. A complete round of transport involves cargo packaging into vesicles, budding and movement of vesicles, and fusion with the target membrane. Arf, coatomer, kinesin and NSF mediate all of these steps, and it has been suggested that some intracellular transport steps depend on lipid signals such as PA [23] . Therefore, for this group of transport proteins, we are in a good position to try to identify the structural basis of PA binding and thus understand the potential role of PA in intracellular traffic.
PA-binding proteins implicated in PLD-dependent pathways
We are characterizing PA binding of two proteins that are proposed to be involved in pathways where PLD is activated. One is PtdIns4P 5-kinase, which phosphorylates PtdIns4P to produce PIP 2 [24] . This enzyme is known to be activated by PA [25] , and cell lines that overexpress PLD1 also exhibit higher levels of PIP 2 synthesis (N.T. Ktistakis and M. Roth, unpublished work). We found that PtdIns4P 5-kinase binds specifically to PA, whereas PtdIns5P 4-kinase (which phosphorylates PtdIns5P to produce PIP 2 , but is not activated by PA) does not. In addition, switching the lipid specificity of the two kinases [26] does not affect PA binding, indicating that the preference for PA does not reflect chemical similarity between PA and PtdIns4P but not PtdIns5P. Another candidate PAbinding protein is sphingosine 1-phosphate kinase (SPHK), which phosphorylates sphingosine to produce sphingosine 1-phosphate [27, 28] . This enzyme is known to be activated by acidic phospholipids such as PA [29] , and its activity in immune cells following cross-linking of the Fc receptor is known to require PLD activation [7] . We found that SPHK binds to PA with high specificity in vitro, whereas it translocates to membranes overexpressing PLD1 in vivo. For both of these proteins, we are trying to identify the structural requirements for PA binding.
Novel proteins
A large number of the putative PA-binding proteins that were identified using the PA-coupled beads are either novel proteins or proteins that have been cloned but whose function is unknown. One such protein is neurochondrin (or norbin) which is specific to the brain and localizes prominently in dendritic outgrowths [30, 31] . We are focusing on neurochondrin because it is one of the most abundant PA-binding proteins in unfractionated brain cytosol and may be a typical representative of PA-binding proteins in general. Neurochondrin-derived fragments were expressed transiently in COS (chimpanzee ovarian sarcoma) cells, and their PA binding was examined. We found that strong PA binding maps to the middle third of neurochondrin, and current work aims to identify the structural features of this fragment that is responsible for PA binding. In addition, we are interested to establish how lipid binding contributes to the localization and function of neurochondrin in brain.
Future directions
PLD-dependent signalling is not mapped at such a resolution as signalling that is mediated by other lipid-modifying enzymes (e.g. phosphoinositide 3-kinase signalling). We still do not have 'knockout' or 'knock-in' transgenic animals with altered PLD activity. In addition, PA binding proteins do not yet constitute a family with common structural characteristics. Work on both of these fronts, and a better understanding of PLD structure-function characteristics, will ultimately allow us to pinpoint with certainty the contribution of this family of enzymes to intracellular signalling. Work in our laboratories is supported by the Biotechnology and Biological Sciences Research Council (BBSRC).
